GT Biopharma (NASDAQ:GTBP) Trading Down 11.1% – Should You Sell?

GT Biopharma, Inc. (NASDAQ:GTBP)’s stock price traded down 11.1% on Monday . The stock traded as low as $0.4170 and last traded at $0.4170. 1,035,586 shares traded hands during mid-day trading, an increase of 26% from the average session volume of 822,522 shares. The stock had previously closed at $0.4693.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e)” rating on shares of GT Biopharma in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GT Biopharma presently has a consensus rating of “Sell”.

GT Biopharma Trading Down 11.1%

The company has a market cap of $4.44 million, a price-to-earnings ratio of -0.06 and a beta of 1.29. The stock has a 50-day simple moving average of $0.60 and a 200-day simple moving average of $0.70.

Institutional Investors Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC bought a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).